ABUS
Price
$3.82Alerts
Change
+$0.10 (+2.69%)
Updated
Nov 10 closing price
Capitalization
724.08M
One day until earnings call
Intraday BUY SELL Signals
PCVX
Price
$66.36Alerts
Change
-$1.17 (-1.73%)
Updated
Nov 10 closing price
Capitalization
9.51B
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs PCVX

ABUS vs PCVX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABUS vs. PCVX commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and PCVX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABUS with price predictions
Nov 10, 2026

ABUS's Indicator enters downward trend

The Aroon Indicator for ABUS entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 180 cases the stock moved lower. This puts the odds of a downward move at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In 63 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for ABUS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 32 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABUS's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in 183 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.799) is normal, around the industry mean (3.498). P/E Ratio (4.627) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for PCVX with price predictions
Nov 10, 2026

PCVX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for PCVX turned positive on November 09, 2026. Looking at past instances where PCVX's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PCVX as a result. In 63 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

PCVX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.

Following a +9.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 222 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 25 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

PCVX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.447) is normal, around the industry mean (3.498). P/E Ratio (-8.374) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
ABUS vs PCVX: Fundamental Ratings
ABUS
PCVX
OUTLOOK RATING
1..100
6711
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
19
Undervalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
1596
PRICE GROWTH RATING
1..100
7341
P/E GROWTH RATING
1..100
5964
SEASONALITY SCORE
1..100
7547

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCVX's Valuation (19) in the null industry is somewhat better than the same rating for ABUS (77) in the Biotechnology industry. This means that PCVX’s stock grew somewhat faster than ABUS’s over the last 12 months.

PCVX's Profit vs Risk Rating (68) in the null industry is in the same range as ABUS (100) in the Biotechnology industry. This means that PCVX’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for PCVX (96) in the null industry. This means that ABUS’s stock grew significantly faster than PCVX’s over the last 12 months.

PCVX's Price Growth Rating (41) in the null industry is in the same range as ABUS (73) in the Biotechnology industry. This means that PCVX’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's P/E Growth Rating (59) in the Biotechnology industry is in the same range as PCVX (64) in the null industry. This means that ABUS’s stock grew similarly to PCVX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSPCVX
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 7 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 10 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
73%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (ABUS: $3.82 vs. PCVX: $66.36)
Brand notoriety: ABUS and PCVX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 47% vs. PCVX: 49%
Market capitalization -- ABUS: $724.08M vs. PCVX: $9.51B
ABUS [@Biotechnology] is valued at $724.08M. PCVX’s [@Biotechnology] market capitalization is $9.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 1 FA rating(s) are green while PCVX’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 1 green, 4 red.
  • PCVX’s FA Score: 1 green, 4 red.
According to our system of comparison, PCVX is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while PCVX’s TA Score has 5 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 4 bearish.
  • PCVX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PCVX is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а -1.55% price change this week, while PCVX (@Biotechnology) price change was +9.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.36%. For the same industry, the average monthly price growth was -9.96%, and the average quarterly price growth was +79.71%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 12, 2026.

PCVX is expected to report earnings on Mar 02, 2027.

Industries' Descriptions

@Biotechnology (-0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with RCKT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+2.69%
RCKT - ABUS
45%
Loosely correlated
-3.16%
MGTX - ABUS
44%
Loosely correlated
+1.37%
PCVX - ABUS
43%
Loosely correlated
-1.73%
ARRY - ABUS
43%
Loosely correlated
-8.86%
AXON - ABUS
42%
Loosely correlated
-0.21%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HTHT50.650.44
+0.88%
H World Group Limited
NRXP2.36-0.02
-0.84%
NRX Pharmaceuticals
ZLAB26.43-0.43
-1.60%
Zai Lab Limited
MGN3.40-0.09
-2.58%
Megan Holdings Limited
EVO1.69-0.05
-2.87%
Evotec SE